The Congressionally Directed Medical Research Program is an office within the US Army Medical Research and Materiel Command that administers competitive grant programs for certain medical research programs that are funded by Congress in the annual Department of Defense appropriation.

The Omnibus Appropriations Bill for FY18 details several funding level changes from previous years. For additional details or questions about how McAllister & Quinn can help your organization compete for funding, contact:

Andy Quinn, Managing Partner
(202) 296-2741
andy@mcallisterquinn.com
# Summary of Funding Levels

<table>
<thead>
<tr>
<th>Research Program</th>
<th>FY15 Enacted (USD, millions)</th>
<th>FY16 Enacted (USD, millions)</th>
<th>FY17 Enacted (USD, millions)</th>
<th>FY18 Omnibus Final (USD, millions)</th>
<th>Final Change, FY18-FY17 (USD, millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol and Substance Abuse</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Amyotrophic Lateral Sclerosis</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$10.0</td>
<td>$2.5</td>
</tr>
<tr>
<td>Autism</td>
<td>$6.0</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$0.0</td>
</tr>
<tr>
<td>Bone Marrow Failure</td>
<td>$3.2</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>$120.0</td>
<td>$120.0</td>
<td>$120.0</td>
<td>$130.0</td>
<td>$10.0</td>
</tr>
<tr>
<td>Duchenne Muscular Dystrophy</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$0.0</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$0.0</td>
</tr>
<tr>
<td>Gulf War Illness</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$21.0</td>
<td>$1.0</td>
</tr>
<tr>
<td>Hearing Restoration Research</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Joint Warfighter Medical</td>
<td>$50.0</td>
<td>$50.0</td>
<td>$50.0</td>
<td>$50.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Kidney Cancer</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$10.0</td>
<td>$15.0</td>
<td>$5.0</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>$10.5</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$14.0</td>
<td>$2.0</td>
</tr>
<tr>
<td>Lupus Research</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Military Burn</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Multiple Sclerosis</td>
<td>$5.0</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Neurofibromatosis</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Orthotics and Prosthetics Outcomes</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Ovarian Cancer</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Parkinson's</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Peer Reviewed Alzheimer's</td>
<td>$12.0</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Peer Reviewed Cancer</td>
<td>$50.0</td>
<td>$50.0</td>
<td>$60.0</td>
<td>$80.0</td>
<td>$20.0</td>
</tr>
<tr>
<td>Peer Reviewed Medical</td>
<td>$247.5</td>
<td>$278.7</td>
<td>$300.0</td>
<td>$330.0</td>
<td>$30.0</td>
</tr>
<tr>
<td>Peer Reviewed Orthopaedic</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Prostate Cancer</td>
<td>$80.0</td>
<td>$80.0</td>
<td>$90.0</td>
<td>$100.0</td>
<td>$10.0</td>
</tr>
<tr>
<td>Psychological</td>
<td>$125.0</td>
<td>$125.0</td>
<td>$125.0</td>
<td>$125.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Reconstructive Transplant Research</td>
<td>$15.0</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Spinal Cord Injury</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Tick-Borne Disease Research</td>
<td>$0.0</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Trauma Clinical</td>
<td>$0.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Tuberous Sclerosis Complex Vision</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Vision</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$0.0</td>
</tr>
</tbody>
</table>
Funding Increases in the FY18 Omnibus Appropriations Bill

The FY18 funding level for the **Amyotrophic Lateral Sclerosis Research Program (ALS)*** (ALSRP) is $10,000,000, which is an increase of $2,500,000 over the FY17 level. The mission of the ALSRP is to fund innovative pre-clinical research to develop new treatments for ALS.

The FY18 funding level for the **Breast Cancer Research Program (BCRP)** is $130,000,000, which is an increase of $10,000,000 over the FY17 level. The mission of the BCRP is to end breast cancer by funding innovative, high-impact research through a partnership of scientists and consumers.

The FY18 funding level for the **Gulf War Illness Research Program (GWIRP)** is $21,000,000, which is an increase of $1,000,000 over the FY17 level. The mission of the GWIRP is to fund innovative Gulf War Illness research to identify effective treatments and accelerate their clinical application, improve definition and diagnosis, and better understand pathobiology and symptoms.

The FY18 funding level for the **Kidney Cancer Research Program (KCRP)** is $15,000,000, which is an increase of $5,000,000 over the FY17 level. The Kidney Cancer Research Program was established as an independent program in FY17 with the mission to promote rigorous, innovative, high impact research in kidney cancer. Kidney Cancer research was previously supported through the CDMRP through the Peer Reviewed Cancer Research Program.

The FY18 funding level for the **Lung Cancer Research Program (LCRP)** is $14,000,000, which is an increase of $2,000,000 over the FY17 level. The mission of the LCRP is to support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer.

The FY18 funding level for the **Peer Reviewed Cancer Research Program (PRCRP)** is $80,000,000, which is an increase of $20,000,000 over the FY17 level. The mission of the PRCRP is to successfully promote high-impact research for cancer prevention, detection, treatment, and survivorship. Topic areas can vary annually. In FY18, the PRCRP is directed to support research in the following areas:

- Adrenal cancer
- Bladder cancer
- Blood cancers
- Brain cancer
- Colorectal cancer
- Immunotherapy
- Listeria-based regimens for cancer
- Liver cancer
- Lymphoma
- Melanoma and other skin cancers
- Mesothelioma
- Myeloma
- Neuroblastoma
- Pancreatic cancer
- Pediatric brain tumors
- Stomach cancer
- Cancer in children, adolescents, and young adults

The FY18 funding level for the **Peer Reviewed Medical Research Program (PRMRP)** is $330,000,000, which is an increase of $30,000,000 over the FY17 level. The mission of the PRMRP is to identify and select military health-related research of exceptional scientific merit. Topic areas vary annually. In FY18, the PRMRP will support 52 topic areas, which is an increase
over the 48 topic areas supported in FY17. In FY18, the PRMRP is directed to support research in the following areas:

- Acute lung injury
- Antimicrobial resistance
- Arthritis
- Burn pit exposure
- Cardiomyopathy
- Cerebellar ataxia
- Chronic migraine and post-traumatic headache
- Chronic pain management
- Congenital heart disease
- Constrictive bronchiolitis
- Diabetes
- Dystonia
- Eating disorders
- Emerging infectious diseases
- Endometriosis
- Epidermolysis bullosa
- Focal segmental glomerulosclerosis
- Fragile X
- Frontotemporal degeneration
- Guillain-Barre syndrome
- Hepatitis B and C
- Hereditary angioedema
- Hydrocephalus
- Immunomonitoring of intestinal transplants
- Inflammatory bowel diseases
- Interstitial cystitis
- Lung injury
- Malaria
- Metals toxicology
- Mitochondrial disease
- Musculoskeletal disorders
- Myotonic dystrophy
- Non-opioid pain management
- Nutrition optimization
- Pancreatitis
- Pathogen-inactivated blood products
- Post-traumatic osteoarthritis
- Pressure ulcers
- Pulmonary fibrosis
- Respiratory health
- Rett syndrome
- Rheumatoid arthritis
- Scleroderma
- Sleep disorders
- Spinal muscular atrophy
- Sustained-release drug delivery
- Tinnitus
- Tissue regeneration
- Tuberculosis
- Vaccine development for infectious disease
- Vascular malformations
- Women’s heart disease

The FY18 funding level for the Prostate Cancer Research Program (PCRP) is $100,000,000, which is an increase of $10,000,000 above the FY17 level. The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease.

Consistent Funding in the FY18 Omnibus Appropriations Bill

The FY18 funding level for the Alcohol and Substance Abuse Disorders Research Program (ASADRP) is $4,000,000, which is consistent with the FY17 level. The mission of the ASADRP is to explore integrated approaches to address alcohol and substance abuse disorders, especially related to TBI and post-traumatic stress disorder (PTSD), through multidisciplinary, team-based research efforts that translate basic knowledge into enhanced clinical pharmacological treatment protocols.

The FY18 funding level for the Autism Research Program (ARP) is $7,500,000, which is
consistent with the FY17 level. The mission of the ARP is to promote innovative research that advances the understanding of autism spectrum disorders and leads to improved outcomes.

The FY18 funding level for the Bone Marrow Failure Research Program (BMFRP) is $3,000,000, which is consistent with the FY17 level. The mission of the BMFRP is to encourage and support innovative research that is committed to advancing the understanding of inherited and acquired bone marrow failure diseases, thereby improving the health of affected individuals, with the ultimate goals of prevention and cure.

The FY18 funding level for the Duchenne Muscular Dystrophy Research Program (DMDRP) is $3,200,000, which is consistent with the FY17 level. The mission of the DMDRP is to support discovery and development of therapeutics, devices, and other interventions, and to promote their rigorous clinical testing for the benefit of military beneficiaries and the general public.

The FY18 funding level for the Epilepsy Research Program (ERP) is $7,500,000, which is consistent with the FY17 level. The mission of the ERP is to fund research to understand the magnitude and the underlying mechanisms of post-traumatic epilepsy, especially in Service members and Veterans.

The FY18 funding level for the Hearing Restoration Research Program (HRRP) is $10,000,000, which is consistent with the FY17 level. The HRRP was initiated in FY17 to advance the science of hearing restoration by delivering groundbreaking research and solutions that remove barriers to the successful treatment of auditory system injury.

The FY18 funding level for the Joint Warfighter Medical Research Program (JWMRP) is $50,000,000, which is consistent with the FY17 level. The mission of the JWMRP is to accelerate research and development projects that have the potential to close high priority Department of Defense medical capability gaps.

The FY18 funding level for the Lupus Research Program (LRP) is $5,000,000, which is consistent with the FY17 level. The LRP was initiated in FY17 with the mission to fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life of patients, including Service members, Veterans, and beneficiaries.

The FY18 funding level for the Military Burn Research Program (MBRP) is $8,000,000, which is consistent with the FY17 level. The mission of the MBRP is to identify gaps in burn trauma care through military focused translational research.

The FY18 funding level for the Multiple Sclerosis Research Program (MSRP) is $6,000,000 for FY17, which is consistent with the FY17 level. The mission of the MSRP is to support pioneering concepts and high impact research relevant to the prevention, etiology, pathogenesis, assessment, and treatment of multiple sclerosis.

The FY18 funding level for the Neurofibromatosis Research Program (NFRP) is $15,000,000, which is consistent with the FY17 level. The mission of the NFRP is to promote research directed towards understanding, diagnosing, and treating neurofibromatosis.
toward the understanding, diagnosis, and treatment of neurofibromatosis (NF) 1, NF2, and schwannomatosis to enhance the quality of life for persons with those disorders.

The FY18 funding level for the Orthotics and Prosthetics Outcomes Research Program (OPORP) is $10,000,000, which is consistent with the FY17 level. The goal of the OPORP is to advance evidence based research in prosthetic and orthotic devices, treatment, rehabilitation, and the prevention of negative secondary health effects of military-related neuromusculoskeletal injury.

The FY18 funding level for the Ovarian Cancer Research Program (OCRP) is $20,000,000, which is consistent with the FY17 level. The mission of the OCRP is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer.

The FY18 funding level for the Parkinson’s Research Program (PPR, funded under the Neurotoxin Exposure Treatment Parkinson’s Research [NETPR] appropriation) is $16,000,000, which is consistent with the FY17 level. The mission of the PRP is to support research to understand, prevent, diagnose, and treat Parkinson’s disease in patients, including Service members and Veterans.

The FY18 funding level for the Peer Reviewed Alzheimer’s Research Program (PRARP) is $15,000,000, which is consistent with the FY17 level. The PRARP is devoted to understanding the association between traumatic brain injury and Alzheimer’s disease (AD) and AD-related dementias; and reducing the burden on affected individuals and caregivers, especially in the military and Veteran communities.

The FY18 funding level for the Peer Reviewed Orthopedic Research Program (PRORP) is $30,000,000, which is consistent with the FY17 level. The mission of the PRORP is to address the most significant gaps in care for the leading burden of injury and loss of fitness for military duty by funding innovative, high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries sustained during combat or combat-related activities.

The FY18 funding level for the Psychological Health/Traumatic Brain Injury Research Program (PH/TBIRP) is $125,000,000, which is consistent with the FY17 level. The mission of the PH/TBIRP is to establish, fund, and integrate both individual and multi-agency research efforts that will lead to improved prevention, detection, and treatment of PH/TBI.

The FY18 funding level for the Reconstructive Transplant Research Program (RTR) is $12,000,000, which is consistent with the FY17 level. The mission of the RTR is to support the development of innovative solutions for the field of vascularized composite allotransplantation to expand public awareness, enhance patient selection, and optimize the restoration of form, function, appearance, and psychosocial health for catastrophically injured military Service members and beneficiaries, Veterans, and American civilians.
The FY18 funding level for the **Spinal Cord Injury Research Program** (SCIRP) is $30,000,000, which is consistent with the FY17 level. The mission of the SCIRP is to fund research and encourage multidisciplinary collaborations for the development and translation of more effective strategies to improve the health and well-being of Service members, Veterans, and other individuals with SCI.

The FY18 funding level for the **Tick-Borne Disease Research Program** (TBDRP) is $5,000,000, which is consistent with the FY17 level. The mission of the TBDRP is to understand the pathogenesis of Lyme disease and other tick-borne illnesses and to deliver innovative solutions to prevent, diagnose, and treat their manifestations for the benefit of US Service members and the American public.

The FY18 funding level for the **Trauma Clinical Research Program** (TCRP) is $10,000,000, which is consistent with the FY17 level. In FY16, a congressional appropriation established the Trauma Clinical Research Program (TCRP) to support the Linking Investigations in Trauma and Emergency Services (LITES) initiative. The program’s mission is to address the military relevant priorities and gaps in trauma care and facilitate the transition of lessons learned into best practice guidance and products. The multi-year indefinite delivery/indefinite quantity LITES network contract was competitively awarded to of the University of Pittsburgh in September 2016.

The FY18 funding level for the **Tuberous Sclerosis Complex Research Program** (TSCRP) is $6,000,000, which is consistent with the FY17 level. The mission of the TSCRP is to fund pioneering and transformative science that promotes new discoveries in TSC, from mechanistic insights to clinical application.

The FY18 funding level for the **Vision Research Program** (VRP) is $15,000,000, which is consistent with the FY17 level. The mission of the VRP is to improve the care of Service members, Veterans, and the American public affected by eye injuries and diseases by identifying clinical needs and addressing them through directed medical research efforts.

---

**About McAllister & Quinn**

McAllister & Quinn provides clients with comprehensive, personalized services to help them execute and exceed their short- and long-term strategic priorities. McAllister & Quinn is recognized as a field leader and has a proven track record of delivering tangible results for clients.